An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Ki vehet részt

• Signed informed consent by participants from previous trial choosing to transition into the Open-label study
• Participants who have successfully completed the preceding trial
• For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit
• For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Ki nem vehet részt

• Participants who experienced any adverse events with ORKA-002 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-002
• Participants whom the Investigator feels would not benefit from treatment with open-label ORKA-002
• Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial
• Participants who, while in ORKA-002-212, developed a new intercurrent illness or diagnosis/suspected diagnosis which, in the opinion of the Investigator, indicates that continued treatment and/or participation in the study is not in the participant's best interest
• Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001
• Participant is pregnant or breastfeeding